Drug Trial Radar · NCT04963270
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
188
Actual
Start
Oct 19, 2021
Primary completion
Jan 29, 2024
Study completion Sep 2, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jul 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).
Conditions
- Generalized Myasthenia Gravis
Interventions
SatralizumabDrug
Satralizumab will be administered as a subcutaneous injection
PlaceboOther
Satralizumab placebo will be administered as a subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Period: Mean Change From Baseline in Total Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the AChR+ PopulationTime frame: At Week 24
Locations
76 sites in 17 countries. Site status is shown where the registry gives one.
Keck School of Medicine of USC
Los Angeles, California
University of California Irvine - Manchester Pavilion
Orange, California
SC3 Research Group, Inc
Pasadena, California
Medical Faculty Associates Inc.
Washington D.C., District of Columbia
University of Chicago Hospital
Chicago, Illinois
Prairie Education and Research
O'Fallon, Illinois
Hospital Italiano
CABA, Argentina
Hospital Ramos Mejía
CABA, Argentina
Hospital Britanico
Ciudad Autonoma Bs As, Argentina
Fundación Scherbovsky
Mendoza, Argentina
INECO Neurociencias Orono
Rosario, Argentina
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas - UNICAMP
Campinas, São Paulo, Brazil
Faculdade de Medicina do ABC - FMABC
Santo André, São Paulo, Brazil
Hospital Sao Paulo
São Paulo, São Paulo, Brazil
MUCH - Montreal Neurological Institute & Hospital
Montreal, Quebec, Canada
Beijing Tongren Hospital
Beijing, China
Beijing Tiantan Hospital,Capital Medical University
Beijing, China
The First Hospital of Jilin University
Changchun, China
West China Hospital - Sichuan University
Chengdu, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
Sir Run Run Shaw Hospital
Hangzhou, China
The First Affiliated Hospital Of Shandong First Medical University
Jinan, China
Huashan Hospital, Fudan University
Shanghai, China
Children's Hospital of Fudan University
Shanghai, China
Tianjin Medical University General Hospital
Tianjin, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Tangdu Hospital
Xi'an, China
Aarhus Universitetshospital
Aarhus N, Denmark
Rigshospitalet
København Ø, Denmark
CHU Bordeaux
Bordeaux, France
APHP Raymond Poincare
Garches, France
Hopital Timone Adultes
Marseille, France
CHU de Nantes - Hotel Dieu
Nantes, France
CHU Nice - Hôpital Pasteur 2
Nice, France
St. Josef-Hospital, Klinik für Neurologie
Bochum, Germany
Universitätsklinikum Essen (AöR)
Essen, Germany
Universitätsklinikum Münster
Münster, Germany
Azienda Ospedaliera A. Cardarelli
Naples, Campania, Italy
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.